NCT05656599View on ClinicalTrials.gov

Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies

Enrolling by invitationOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
CMV InfectionHematopoietic Stem Cell Transplantation
Interventions
DRUG

Letermovir

Patients received letermovir as prophylaxis or received preemptive therapy for CMV depends on clinical needs and patients' wishes

Trial Locations (2)

100044

Department of Hematology, Peking University People's Hospital, Beijing

Unknown

People's Hospital of Peking University, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER